Cyclacel places UK subsidiary into CVL; to buy plogosertib, sell fadraciclib

Bio Green Med Solution, Inc.

UK subsidiary Cyclacel Ltd entered creditors voluntary liquidation; joint liquidators appointed.
Company plans to purchase plogosertib from liquidators for new oral formulation development.
Fadraciclib program will be marketed for sale by liquidators and removed from company assets.
Deconsolidation expected to increase stockholders' equity by approximately $5.6M in Q1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.